Aetion adds strategic investment from Johnson & Johnson Innovation - JJDC, Inc., EDBI, Greenspring Associates to expand RWE offerings Funding completes $82 million Series B round with the addition of $19 million, will further accelerate Aetion's role as a global leader in regulatory-grade evidence NEW YORK, August 26, 2020-- Today, Aetion, a health care technology company that delivers real-world evidence (RWE) for biopharma companies, payers, and regulatory agencies, announced a $19 million extension to its Series B funding round, with investment from three new shareholders: Johnson & Johnson Innovation – JJDC, Inc. (JJDC), EDBI, and Greenspring Associates.